The healthcare giant posted adjusted earnings per share of $2.82, exceeding analysts' predictions by $0.10, and a revenue of $22.45 billion, also topping the consensus estimate of $22.34 billion.
Johnson & Johnson's financial results showed a 10.2% increase in adjusted EPS despite a 5.9% decrease in reported EPS due to one-time special charges. Looking ahead, Johnson & Johnson has raised its full-year 2024 operational sales guidance, reflecting the acquisition of Shockwave Medical and updates to its adjusted operational EPS guidance to account for improved performance and recent strategic acquisitions.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: